GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (STU:2CB0) » Definitions » Cyclically Adjusted PB Ratio

Calithera Biosciences (STU:2CB0) Cyclically Adjusted PB Ratio : (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Calithera Biosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Calithera Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences Cyclically Adjusted PB Ratio Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.06

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.06

Competitive Comparison of Calithera Biosciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Calithera Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calithera Biosciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's Cyclically Adjusted PB Ratio falls into.



Calithera Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Calithera Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2022 is calculated as:

For example, Calithera Biosciences's adjusted Book Value per Share data for the three months ended in Dec. 2022 was:

Adj_Book=Book Value per Share/CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-0.378/125.2218*125.2218
=-0.378

Current CPI (Dec. 2022) = 125.2218.

Calithera Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201212 -16.534 96.871 -21.373
201306 0.000 98.518 0.000
201309 0.000 98.790 0.000
201312 -38.463 98.326 -48.984
201403 0.000 99.695 0.000
201406 22.466 100.560 27.976
201409 -30.389 100.428 -37.892
201412 90.728 99.070 114.678
201503 95.874 99.621 120.512
201506 85.547 100.684 106.396
201509 77.230 100.392 96.332
201512 72.292 99.792 90.714
201603 63.761 100.470 79.469
201606 54.502 101.688 67.115
201609 47.707 101.861 58.648
201612 44.007 101.863 54.099
201703 87.820 102.862 106.910
201706 81.559 103.349 98.820
201709 74.775 104.136 89.916
201712 71.036 104.011 85.522
201803 66.942 105.290 79.615
201806 70.057 106.317 82.514
201809 62.614 106.507 73.616
201812 57.363 105.998 67.766
201903 47.994 107.251 56.036
201906 45.881 108.070 53.163
201909 40.747 108.329 47.101
201912 40.364 108.420 46.619
202003 35.722 108.902 41.075
202006 36.065 108.767 41.521
202009 29.503 109.815 33.642
202012 23.809 109.897 27.129
202103 21.410 111.754 23.990
202106 18.593 114.631 20.311
202109 17.070 115.734 18.469
202112 1.923 117.630 2.047
202203 -0.723 121.301 -0.746
202206 2.510 125.017 2.514
202209 0.840 125.227 0.840
202212 -0.378 125.222 -0.378

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Calithera Biosciences  (STU:2CB0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Calithera Biosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Calithera Biosciences (STU:2CB0) Business Description

Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Calithera Biosciences (STU:2CB0) Headlines

No Headlines